Get the Stockscreener App
21.64
3.82%
-0.86
After Hours:
21.64
Overview
News
Price History
Option Chain
Why FMS Down?
Discussions
Forecast
Stock Split
Dividend History
Fresenius Medical Care Ag Adr stock is traded at $21.64, with a volume of 390.10K.
It is down -3.82% in the last 24 hours and down -5.34% over the past month.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
See More
Previous Close:
$22.50
Open:
$21.66
24h Volume:
390.10K
Relative Volume:
0.60
Market Cap:
$11.62B
Revenue:
$22.18B
Net Income/Loss:
$1.36B
P/E Ratio:
11.26
EPS:
1.9216
Net Cash Flow:
$2.00B
1W Performance:
+0.19%
1M Performance:
-5.34%
6M Performance:
-7.56%
1Y Performance:
-26.19%
1-Day Range:
$21.59
$21.81
1-Week Range:
$21.59
$22.59
52-Week Range:
$20.02
$29.71
Fresenius Medical Care Ag Adr Stock (FMS) Company Profile
Name
Fresenius Medical Care Ag Adr
Sector
Industry
Phone
-
Address
-
Compare FMS vs HCA, THC, DVA, EHC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FMS
Fresenius Medical Care Ag Adr
|
21.64 | 12.09B | 22.18B | 1.36B | 2.00B | 1.9216 |
HCA
Hca Healthcare Inc
|
394.07 | 87.09B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
173.78 | 15.33B | 21.46B | 2.65B | 3.35B | 19.23 |
DVA
Davita Inc
|
198.52 | 12.75B | 13.84B | 1.10B | 1.49B | 10.42 |
EHC
Encompass Health Corp
|
104.96 | 10.36B | 6.07B | 793.80M | 464.40M | 5.9914 |
Fresenius Medical Care Ag Adr Stock (FMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Goldman | Buy → Neutral |
| Oct-15-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-02-25 | Downgrade | UBS | Neutral → Sell |
| Dec-02-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-06-24 | Initiated | Berenberg | Buy |
| Jan-08-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-24-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-17-23 | Upgrade | Societe Generale | Hold → Buy |
| Aug-14-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Resumed | Citigroup | Neutral |
| Jul-12-23 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | Bernstein | Mkt Perform |
| Jan-03-23 | Downgrade | Jefferies | Buy → Underperform |
| Oct-26-22 | Downgrade | Deutsche Bank | Hold → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-27-22 | Upgrade | Jefferies | Underperform → Buy |
| Feb-11-22 | Downgrade | Jefferies | Hold → Underperform |
| Nov-23-21 | Initiated | HSBC Securities | Hold |
| Nov-11-21 | Upgrade | Jefferies | Underperform → Hold |
| Feb-04-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-03-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| May-20-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-21-20 | Upgrade | Jefferies | Hold → Buy |
| Jun-20-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-26-18 | Upgrade | UBS | Neutral → Buy |
| Aug-28-18 | Upgrade | HSBC Securities | Hold → Buy |
| Jul-05-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-04-18 | Upgrade | UBS | Sell → Neutral |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-01-16 | Reiterated | RBC Capital Mkts | Sector Perform |
| Sep-06-16 | Upgrade | Citigroup | Neutral → Buy |
| Jul-08-16 | Upgrade | Jefferies | Underperform → Hold |
| Jan-04-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-04-15 | Reiterated | RBC Capital Mkts | Sector Perform |
| Sep-03-15 | Upgrade | Goldman | Neutral → Buy |
| Aug-13-15 | Downgrade | Societe Generale | Buy → Hold |
| Jul-31-15 | Reiterated | RBC Capital Mkts | Sector Perform |
| Aug-02-13 | Reiterated | Feltl & Co. | Hold |
| Jan-14-13 | Upgrade | HSBC Securities | Neutral → Overweight |
View All
Fresenius Medical Care Ag Adr Stock (FMS) Latest News
Research in Brief: Online hemodiafiltration and medium cut-off dialyzers - Fresenius Medical Care
Fresenius Medical Care stock (DE0005785802): Dividend vote and guidance shape the 2026 setup - AD HOC NEWS
Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care - Fresenius Medical Care
Fresenius Medical Care stock (DE0005785802): New focus on dialysis demand and margin discipline - AD HOC NEWS
Fresenius Medical Care reappoints CFO Martin Fischer until 2031 - Investing.com
Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer - Morningstar
Fresenius Medical Care stock (DE0005785802): earnings update and strategy focus - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): dialysis specialist in focus after latest quarterly upd - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): New dialysis trends keep the company in focus - AD HOC NEWS
Ready4 Ci-Ca: Innovation in clinical education - Fresenius Medical Care
Fresenius Medical Care: Shares Look Attractive, Despite Market Uncertainty Around Margin Trajectory - Morningstar
Fresenius Medical Care AG (FMS) Stock Price, Trades & News - GuruFocus
Fresenius SE & Co. KGaA stock (DE0005785604): Global healthcare giant with US dialysis exposure - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): Dialysis giant faces headwinds and opportunities in 202 - AD HOC NEWS
Fresenius Medical Care Q1 2026 slides: margin expansion amid revenue pressures - Investing.com Australia
Fresenius Medical Care Q1 2026 slides: margin expansion amid revenue pressures By Investing.com - Investing.com South Africa
Fresenius Medical Care's Margin Improvement Looks Just Paused in 2026, Not Over - Morningstar
Earnings call transcript: Fresenius Medical Care Q1 2026 beats EPS expectations - Investing.com
Fresenius Medical Care Q1 shares fall on U.S. treatment slowdown - Investing.com
Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed - Fresenius Medical Care
Fresenius Medical Care stock (DE0005785802): Is chronic kidney disease demand strong enough to unloc - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): Why Google Discover changes matter more now - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): Is U.S. dialysis dominance still the key growth engine? - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): Why U.S. dialysis demand now drives the real value test - AD HOC NEWS
Fresenius Medical Care stock (DE0005785802): Is U.S. dialysis dominance still the key growth lever? - AD HOC NEWS
Research in Brief: Immunosuppressive therapies in kidney transplant recipients - Fresenius Medical Care
Fresenius Medical Care Sets May 21, 2026 AGM With Dividend and New Buyback Mandate on Agenda - TipRanks
Fresenius Medical Care (NYSE: FMS) plans €1.49 dividend and renews 10% buyback mandate - Stock Titan
Fresenius Medical Care stock: What you should know now before buying - AD HOC NEWS
Supporting living donors through the Circle of Excellence - Fresenius Medical Care
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now - Zacks Investment Research
Fresenius Medical Care stock advances FME Reignite strategy with Interwell Health investment amid st - AD HOC NEWS
10 New 5-Star Stocks This Week - Morningstar
Fresenius Medical Care publishes its Annual Report 2025: The power of care - Fresenius Medical Care
Research round-up: Innovation that moves kidney care forward - Fresenius Medical Care
Advancing kidney care: Introducing high-volume hemodiafiltration to the U.S. - Fresenius Medical Care
Fresenius Medical Care Faces a Transition Year in 2026 on New Product Launch Activities - Morningstar
Fresenius Medical Care marks World Kidney Day and National Kidney Month - Fresenius Medical Care
Fresenius Medical Care's 2030 Ambition: Navigating a Pivotal Transition () - aktiencheck.de
Fresenius Medical Care: An Undervalued Stock to Buy Now and Hold for the Long Term - Morningstar
5 Undervalued Stocks That Crushed Q4 Earnings - Morningstar
FMS Stock Rises as Q4 Earnings & Sales Beat Estimates, Margins Expand - Finviz
Research in Brief: Nocturnal home hemodialysis - Fresenius Medical Care
Fresenius Medical Care ADR earnings beat by $1.11, revenue topped estimates - Investing.com Australia
Fresenius Medical Care published Report on Form 20-F for fiscal year 2025 - Fresenius Medical Care
Fresenius Medical Care Q4 2025 slides: margin surge, flat 2026 outlook - Investing.com
Earnings call transcript: Fresenius Medical Care Q4 2025 beats EPS expectations - Investing.com
Fresenius Medical Care falls nearly 7% despite earnings beat - Investing.com South Africa
Fresenius Medical Care falls 7% after 2026 flat growth outlook and cost update - Investing.com
Research in Brief: Hemodiafiltration and hospitalization burden in ESKD - Fresenius Medical Care
Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band - Fresenius Medical Care
Fresenius Medical Care Ag Adr Stock (FMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):